Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTXNASDAQ:MGRXNASDAQ:MRAINASDAQ:VSEE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBioRestorative Therapies$1.71+1.2%$1.73$1.03▼$2.55$12.83M68.9620,389 shs30,621 shsMGRXMangoceuticals$1.81-13.8%$3.17$1.49▼$16.80$9.36M2.41270,239 shs3.73 million shsMRAIMarpai$1.00$0.96$0.40▼$2.68$14.90M4.7520,777 shs56,754 shsVSEEVsee Health$1.27$1.27$1.00▼$14.47$4.58MN/A1.17 million shs16,098 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBioRestorative Therapies0.00%-2.29%-5.52%-25.65%+36.80%MGRXMangoceuticals0.00%-29.57%-23.95%-34.89%-96.94%MRAIMarpai0.00%-4.76%0.00%+4.30%-54.13%VSEEVsee Health0.00%+6.45%+13.39%-19.62%+126,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXBioRestorative Therapies3.8411 of 5 stars3.55.00.00.02.93.31.3MGRXMangoceuticals1.0571 of 5 stars0.04.00.00.03.31.70.0MRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/AVSEEVsee Health1.9028 of 5 stars2.04.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBioRestorative Therapies 3.00Buy$18.00952.63% UpsideMGRXMangoceuticals 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/AVSEEVsee Health 4.00Strong Buy$5.00293.70% UpsideCurrent Analyst Ratings BreakdownLatest VSEE, MRAI, MGRX, and BRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/24/2025VSEEVsee HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.002/21/2025VSEEVsee HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBioRestorative Therapies$401K32.00N/AN/A$2.45 per share0.70MGRXMangoceuticals$615.87K15.19N/AN/A$0.54 per share3.35MRAIMarpai$34.87M0.43N/AN/A($1.72) per share-0.58VSEEVsee Health$6.38M0.72N/AN/A($3.40) per share-0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBioRestorative Therapies-$14.41M-$1.16N/AN/AN/A-2,697.08%-98.49%-75.23%5/12/2025 (Estimated)MGRXMangoceuticals-$9.21M-$4.85N/A∞N/A-1,237.00%-138.00%-118.88%5/21/2025 (Estimated)MRAIMarpai-$28.75M-$2.07N/A∞N/A-85.70%N/A-100.23%5/5/2025 (Estimated)VSEEVsee Health-$4.41MN/A0.00∞N/AN/A-182.59%-58.26%N/ALatest VSEE, MRAI, MGRX, and BRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024BRTXBioRestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million3/20/2025Q4 2024MGRXMangoceuticalsN/A-$1.01N/A-$1.01N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBioRestorative TherapiesN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AVSEEVsee HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBioRestorative TherapiesN/A2.952.95MGRXMangoceuticalsN/A0.070.07MRAIMarpaiN/A0.820.82VSEEVsee Health0.160.370.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBioRestorative Therapies69.38%MGRXMangoceuticals56.72%MRAIMarpai49.75%VSEEVsee Health1.01%Insider OwnershipCompanyInsider OwnershipBRTXBioRestorative Therapies25.50%MGRXMangoceuticals16.00%MRAIMarpai61.30%VSEEVsee Health6.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBioRestorative Therapies77.51 million5.16 millionNot OptionableMGRXMangoceuticals35.17 million1.51 millionNot OptionableMRAIMarpai15014.90 million5.61 millionNo DataVSEEVsee HealthN/A3.60 million3.37 millionN/AVSEE, MRAI, MGRX, and BRTX HeadlinesRecent News About These CompaniesCovalon Technologies (OTCMKTS:CVALF) vs. Vsee Health (NASDAQ:VSEE) Head-To-Head ContrastApril 19, 2025 | americanbankingnews.comVSee Health unveils AI-driven telenursing platformApril 18, 2025 | uk.investing.comVSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing CostsApril 16, 2025 | finance.yahoo.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare Market Featured Image featured image Admin MessageApril 2, 2025 | markets.businessinsider.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketApril 2, 2025 | prnewswire.comVSee Health issues letter to shareholders updating progressMarch 7, 2025 | markets.businessinsider.comVSee Issues Shareholder Letter Highlighting 2024 Achievements and Strong Growth Outlook for 2025March 6, 2025 | finance.yahoo.comVSee Health wins telehealth contract for mental health servicesMarch 6, 2025 | finance.yahoo.comVSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector HealthcareMarch 5, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | businesswire.comMaxim Group Initiates Coverage of VSee Health (VSEE) with Buy RecommendationFebruary 25, 2025 | msn.comVSee Health initiated with a Buy at MaximFebruary 24, 2025 | markets.businessinsider.comMaxim starts VSee Health at Buy, sees good momentum in new contractsFebruary 24, 2025 | markets.businessinsider.comVSee Health signs $560,000 contract with oncology networkFebruary 20, 2025 | markets.businessinsider.comAI in Healthcare Sees Explosive Growth: Key Innovations Investors Should WatchFebruary 11, 2025 | baystreet.caVSee Health renews two-year contract worth $2m with IDN hospital systemFebruary 7, 2025 | msn.comVSee Health Secures $2M Contract Renewal for Neurocritical Care Expansion at Leading Hospital SystemFebruary 7, 2025 | finance.yahoo.comVSee Healthl renews $2M two-year contract with IDN hospital systemFebruary 7, 2025 | markets.businessinsider.comVSee Health wins $340K EHR and virtual care contractFebruary 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSEE, MRAI, MGRX, and BRTX Company DescriptionsBioRestorative Therapies NASDAQ:BRTX$1.71 +0.02 (+1.18%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Mangoceuticals NASDAQ:MGRX$1.81 -0.29 (-13.81%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Marpai NASDAQ:MRAI$1.00 0.00 (0.00%) As of 04/25/2025 03:50 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.Vsee Health NASDAQ:VSEE$1.27 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.26 -0.01 (-0.79%) As of 04/25/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
